170381-16-5

Upstream product

• 65565-15-3 6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-one 
• 84477-72-5 2,2-dimethylpiperazine 
• 116617-20-0 3-Amino-5-chloro-1-cyano-1-phenyl-1H-indene-2-carboxylic acid methyl ester 
• 153627-83-9 2,2-dimethyl-1,2,5,6-tetrahydropyrazine 
• 170380-92-4 6-Chloro-3-phenyl-indan-1-ol 
• 846052-64-0 trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine 
• 50-00-0 formaldehyd 
• 64-18-6 formic acid 
• 170381-17-6 Zicronapine fumarate 

Downstream Products

• 170381-17-6 Zicronapine fumarate 
• 846061-36-7 trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen succinate 
• 846541-66-0 trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen malonate 

Relevant academic research and scientific papers

PROCESS FOR MAKING TRANS-1-((1R, 3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-3, 3-DIMETHYLPIPERAZINE

Described is a method for making the trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine (formula I) and salts thereof and a similar method for making 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine (formula IX) and salt

SUCCINATE AND MALONATE SALT OF TRANS-4-(IR,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND THE USE AS A MEDICAMENT

4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen succinate or hadrogen malonat, pharmaceutical compositions containing these salts and the medical use thereof, including for the treatment of schizophrenia and other psychotic diso

Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindans with Potential Atypical Antipsychotic Activity

A study of the effect of aromatic substitution on D1 and D2 affinity in a series of previously reported trans-1-piperazino-3-phenylindans shows similar structure-activity relationships for the two receptor sites. 6-Substituted derivatives have affinity for both receptors, and 6-chloro-or 6-fluoro-substituted derivatives show preference for D1 receptors.D1 affinity and selectivity are significantly increased in a series of new piperazine ring substituted derivatives.Potent D1 and D2 antagonism in vivo are confined to derivatives with relatively small substituents in the 2-position of the piperazine ring (e.g. 2-methyl, 2,2-dimethyl, 2-spirocyclobutyl or 2-spiro-cyclopentyl).Consequently, the effect of aromatic substitution is examined in a series of 1-(2,2-dimethylpiperazino)-3-arylindans.All these compounds except the 4-, 5-, 7- and 4'-chloro-substituted derivatives have potent D1 affinity (IC50's below 10 nM) and the majority of the compounds antagonize SKF 38393-induced circling in 6-OHDA-lesioned rats with ED50 values about 1μmol/kg.In vitro all compounds show preference for D1 receptors, but in vivo they are equally effective as D1 and D2 antagonists.The compounds have high affinity for 5-HT2 receptors and selected compounds show high affinity for α1 adrenoceptors.Furthermore, a subgroup consisting of (-)-38, (-)-39, (-)-41, and (-)-54 does not induce catalepsy in rats.These compounds have the potential of being "atypical" antipsychotics and have consequently been selected for further studies.The non-receptor-blocking enantiomers are shown to be inhibitors of DA and NE uptake in accordance with previous observations in compounds unsubstituted in the piperazinering.Two compounds, (+)-38 and (+)-40, block DA uptake with IC50 values below 10nM.Finally, the observed structure-activity relationships are discussed in relation to previously published pharmacophore models for D2 and 5-HT2 receptors.It is concluded that the piperazine substituents might induce a different binding mode at the dopamine receptor sites, perhaps only at the D1 receptor site.